Literature DB >> 16487283

Quality of life and depression in a population of occupational hand eczema patients.

Rikke Skoet Cvetkovski1, Robert Zachariae, Henrik Jensen, Jørn Olsen, Jeanne Duus Johansen, Tove Agner.   

Abstract

Occupational hand eczema (OHE) is the most frequently recognized occupational disease in Denmark, and despite governmental attempts to reduce exposure to harmful occupational allergens, the number of new cases has remained almost unchanged since the mid-1990s. Some studies have indicated that OHE has considerable impact on quality of life (QoL) and may lead to depression. The aims of the study were to determine risk factors for low QoL, the frequency and severity of depression among OHE patients and changes in QoL and depression after 12 months of follow up. The study population, 758 patients, comprised all new recognized cases from the Danish National Board of Industrial Injuries Registry between October 2001 and November 2002. All patients received a questionnaire to determine impairment of QoL and depressive symptoms. A similar follow-up questionnaire was posted after 1 year. The response rate was 82% at baseline and 91% at follow up. The mean Dermatology Life Quality Index total score was 5.5 for all patients and 7.8 for severe OHE cases. Severe OHE cases and lower socioeconomic status were independently associated with low QoL. The prevalence of moderate-to-severe depression was 9%. Only minor changes in QoL and depressive symptoms were found after 12 months of follow up.

Entities:  

Mesh:

Year:  2006        PMID: 16487283     DOI: 10.1111/j.0105-1873.2006.00783.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  26 in total

1.  PPE-associated dermatoses: effect on work and wellbeing.

Authors:  Aarthy K Uthayakumar; Evangelia Panagou; Seshi Manam; Anna Schauer; Ophelia Veraitch; Steve Walker; Emma Edmonds; Jennifer Crawley; Claire Martyn-Simmons
Journal:  Future Healthc J       Date:  2021-03

Review 2.  [Health services research: the example of hand eczema].

Authors:  C J Apfelbacher; T L Diepgen
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

3.  [Rehabilitation for occupational dermatoses. Outpatient and inpatient measures].

Authors:  H Schwantes; S Schliemann; P Elsner
Journal:  Hautarzt       Date:  2010-04       Impact factor: 0.751

4.  Health-Related Quality of Life Among US Workers: Variability Across Occupation Groups.

Authors:  Taylor M Shockey; Matthew Zack; Aaron Sussell
Journal:  Am J Public Health       Date:  2017-06-22       Impact factor: 9.308

5.  The Hand Eczema Trial (HET): Design of a randomised clinical trial of the effect of classification and individual counselling versus no intervention among health-care workers with hand eczema.

Authors:  Kristina Sophie Ibler; Tove Agner; Jane Lindschou Hansen; Christian Gluud
Journal:  BMC Dermatol       Date:  2010-08-31

Review 6.  [Chronic hand eczema: epidemiology and therapeutic evidence].

Authors:  T L Diepgen
Journal:  Hautarzt       Date:  2008-09       Impact factor: 0.751

7.  Chronic hand eczema--self-management and prognosis: a study protocol for a randomised clinical trial.

Authors:  Annette Mollerup; Niels Kren Veien; Jeanne Duus Johansen
Journal:  BMC Dermatol       Date:  2012-06-12

8.  Impact of hand eczema severity on quality of life.

Authors:  Ujwala Priya Charan; C V Dincy Peter; Susanne A Pulimood
Journal:  Indian Dermatol Online J       Date:  2013-04

9.  Particle transfer and adherence to human skin compared with cotton glove and pre-moistened polyvinyl alcohol exposure sampling substrates.

Authors:  Aleksandr B Stefaniak; Eleanor E Wade; Robert B Lawrence; Elizabeth D Arnold; M Abbas Virji
Journal:  J Environ Sci Health A Tox Hazard Subst Environ Eng       Date:  2021-03-15       Impact factor: 2.269

10.  The Quality of Life and Depressive Mood among Korean Patients with Hand Eczema.

Authors:  Mi Yu; Tae Young Han; June Hyunkyung Lee; Sook-Ja Son
Journal:  Ann Dermatol       Date:  2012-11-08       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.